JP2024537839A5 - - Google Patents
Info
- Publication number
- JP2024537839A5 JP2024537839A5 JP2024519989A JP2024519989A JP2024537839A5 JP 2024537839 A5 JP2024537839 A5 JP 2024537839A5 JP 2024519989 A JP2024519989 A JP 2024519989A JP 2024519989 A JP2024519989 A JP 2024519989A JP 2024537839 A5 JP2024537839 A5 JP 2024537839A5
- Authority
- JP
- Japan
- Prior art keywords
- ch2oco
- compound
- och2ch2
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255998P | 2021-10-15 | 2021-10-15 | |
| US63/255,998 | 2021-10-15 | ||
| PCT/US2022/046750 WO2023064578A1 (en) | 2021-10-15 | 2022-10-14 | Prodrugs of axitinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537839A JP2024537839A (ja) | 2024-10-16 |
| JP2024537839A5 true JP2024537839A5 (enExample) | 2025-10-06 |
Family
ID=85987895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519989A Pending JP2024537839A (ja) | 2021-10-15 | 2022-10-14 | アキシチニブのプロドラッグ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250092013A1 (enExample) |
| EP (1) | EP4416132A4 (enExample) |
| JP (1) | JP2024537839A (enExample) |
| CN (1) | CN118119599A (enExample) |
| AU (1) | AU2022362310A1 (enExample) |
| CA (1) | CA3232086A1 (enExample) |
| MX (1) | MX2024003968A (enExample) |
| WO (1) | WO2023064578A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024081410A1 (en) * | 2022-10-14 | 2024-04-18 | Ocular Therapeutix, Inc. | Prodrugs, formulations and methods thereof |
| AU2024251447A1 (en) | 2023-04-11 | 2025-08-21 | Ocular Therapeutix, Inc. | Ocular implant comprising axitinib polymorph iv |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5721949B2 (ja) * | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| TWI664965B (zh) * | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
| US20210078970A1 (en) * | 2019-08-30 | 2021-03-18 | Risen (Suzhou) Pharma Tech Co., Ltd. | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
| WO2021035360A1 (en) * | 2019-08-30 | 2021-03-04 | Risen (Suzhou) Pharma Tech Co., Ltd. | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
| CN112442010B (zh) * | 2019-08-30 | 2023-10-03 | 润佳（苏州）医药科技有限公司 | 一类前药化合物及其在治疗癌症方面的应用 |
-
2022
- 2022-10-14 CN CN202280066784.0A patent/CN118119599A/zh active Pending
- 2022-10-14 CA CA3232086A patent/CA3232086A1/en active Pending
- 2022-10-14 JP JP2024519989A patent/JP2024537839A/ja active Pending
- 2022-10-14 WO PCT/US2022/046750 patent/WO2023064578A1/en not_active Ceased
- 2022-10-14 AU AU2022362310A patent/AU2022362310A1/en active Pending
- 2022-10-14 US US18/706,306 patent/US20250092013A1/en active Pending
- 2022-10-14 MX MX2024003968A patent/MX2024003968A/es unknown
- 2022-10-14 EP EP22881846.4A patent/EP4416132A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250345321A1 (en) | Catequentinib (anlotinib) in sequential combination with immunotherapy for use in the treatment of cancer | |
| JP2023098946A5 (enExample) | ||
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| TW469132B (en) | Antiviral combinations | |
| JP2021519764A5 (enExample) | ||
| AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| AU702618B2 (en) | 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2 -cyclopentene-1-methanol succinate as antiviral agent | |
| EP2814493A2 (en) | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof | |
| KR20110089851A (ko) | 비대 심근병증의 치료를 위한 포스포디에스테라제 타입 Ⅲ（ＰＤＥ Ⅲ） 억제제 또는 Ｃａ２＋―감작제 | |
| JP2013536243A5 (enExample) | ||
| ZA200106439B (en) | Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity. | |
| WO2020238932A1 (zh) | Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途 | |
| CA3166379A1 (en) | Inhibitors of glutathione s-transferases (gsts) and nad(p)h:quinone oxidoreductase 1 (nqo1), pharmaceutical compositions, and uses in managing cancer | |
| RU2007101522A (ru) | Диарилметилпиперазиновые производные, их получение и применение | |
| CN115867281A (zh) | 治疗肺纤维化的方法 | |
| US20100130554A1 (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease | |
| CN1362877A (zh) | 用于治疗神经变性的方法 | |
| CN102440957A (zh) | 醋酸特利加压素鼻腔喷雾剂及其制备方法 | |
| JP2018508559A5 (enExample) | ||
| JP4646921B2 (ja) | マレイン酸イボパミンを含む医薬組成物及びその製造方法 | |
| US20180021276A1 (en) | Bezafibrate for the treatment of cancer | |
| JPH11315019A (ja) | 腎透析に伴うそう痒の治療剤 | |
| US20260124181A1 (en) | Agent for reducing blood myostatin level | |
| CN121419773A (zh) | 用于预防或治疗肺纤维化的达可替尼和尼达尼布的联合疗法 | |
| CN115427033B (zh) | 用于治疗选自脓毒症、脓毒症休克、急性呼吸窘迫综合征(ards)或多器官功能障碍综合征(mods)的疾病的nk-1受体拮抗剂 |